SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cellectar Biosciences Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Douglas Hall11/22/2016 10:31:55 AM
   of 46
 
Cellectar Biosciences Inc CLRB 4.11%, a nano-cap oncology-focused clinical-stage company, announced on Tuesday a new collaboration to better explore a phase 2 clinical trial.

Cellectar selected INC Research Holdings Inc INCR 0.94%, a leading contract research organization, to oversee its Phase 2 clinical trial of CLR 131 in patients with multiple myeloma and select hematologic malignancies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News